Q-omics provides the consensus-scored LINC02881 profile across patient tissues and cancer cell-line models. LINC02881 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, LINC02881 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, LINC02881 RNA expression shows 9,521 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight OV, KIRC, and KIRP as cancer lineages where LINC02881 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02881 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02881 survival associations across molecular data types. LINC02881 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02881 RNA expression–survival associations across cancer types. High LINC02881 expression shows unfavorable associations in OV, UVM and LUSC, but favorable associations in THCA, ESCA and UCS. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for LINC02881 RNA expression.
This table summarizes LINC02881 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02881. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02881 shows lower tumor expression in KICH, BLCA, COAD and BRCA and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher LINC02881 RNA expression in tumor versus normal tissue (log2 FC = +0.278, t-test p < 0.001).
This table shows molecular features associated with LINC02881 in patient tissues and cancer cell lines. In patient samples, LINC02881 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC02881 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
